Group 1C: Metastatic Breast Cancer; HER2+; Antibody Drug Conjugates; Treatment Resistance; Novel Drug

Poster #P1-01-27: HER2 Loss Following Treatment with Trastuzumab Deruxtecan in Patients with Metastatic Breast Cancer

Poster #P2-10-20: ACE-BREAST-03: A phase 2 trial evaluating ARX788, an anti-HER2 antibody drug conjugate (ADC), for the treatment of HER2+ metastatic breast cancer (mBC) in patients who have been previously treated with trastuzumab deruxtecan (T-DXd)